Fractyl Labs CEO Harith Rajagopalan envisions a scenario in which those with type 2 diabetes don’t have to rely on insulin injections.
Insulin has long been a staple of treatment for type 2 diabetes patients who need to manage their blood sugar levels, but Rajagopalan’s aim is to go beyond that temporary fix with Fractyl Labs.
“We started to think hard about what is the root cause of type 2 diabetes and how might we develop therapies that might target the root cause to change the trajectory of disease and not just put a band-aid on its symptoms,” Rajagopalan told Drug Delivery Business News. “That’s what led us to start Fractyl about 10 years ago.”
Get the full story at our sister site, Drug Delivery Business News.